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The National Lung Cancer Screening Trial (NLST) is a cooperative, National CancerInstitute (NCI)-sponsored randomized trial that was initiated in 2002 with the primary
goal to determine whether screening for lung cancer with computed tomography (CT),
when compared with chest radiographs, reduces lung cancer specific mortality. The trial
represented a merger of two NCI-sponsored activities, the NCI Lung Screening Study and
the American College of Radiology Imaging Network (ACRIN). It enrolled more than
50,000 high-risk individuals (heavy current cigarette smokers or former smokers) from
more than 30 sites across the United States. The ACRIN arm (ACRIN 6654) accrued
18,842 participants. These participants, aged 55 to 74 years, will be followed up for at
least 5 years after enrollment, which was complete in February 2004, to determine
whether low-dose helical CT reduces lung cancer deaths relative to chest radiographs.
Details concerning the design of this trial can be found on the National Institutes of Health
(NIH)-NCI website (http://www.cancer.gov/nlst/what-is-nlst).
As part of this large, unique screening opportunity, biospecimens were collected
with the fundamental goal of validating biomarkers that have been carefully tested in pilot
data complement or replace imaging for early detection of lung cancer.1 Serial blood,
sputum, and urine samples were collected using a standardized protocol on approximately
10,300 NLST ACRIN participants. Specifically, the blood and urine samples were
collected by the study center at the time of each screening visit, whereas the sputum was
collected by the participant at home and shipped by the participant to the central
biorepository. The specimens are stored in a central biorepository and linked through a
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unique participant identifier to extensive clinical data. This
report briefly describes the biorepository, its intent, and its
availability for investigators interested in biomarker valida-
tion studies in early detection of lung cancer.
BIOREPOSITORY DESCRIPTION
The biorepository consists of approximately 107,000
each of buffy coat and plasma samples—participants could
provide as many as 12 blood samples (four vials at each
screening)—54,600 urine samples—participants could pro-
vide as many as six samples (two vials at each screening), and
36,000 sputum cell pellet specimens—participants could pro-
vide as many as six samples (two cups at each screening). Of
approximately 10,300 participants, more than 99% provided
at least one blood sample (including buffy coat and plasma)
and at least one urine sample, and more than 74% provided
these samples at all three screenings. Approximately 80%
provided at least one sputum sample to produce cell pellet,
and approximately 27% provided sputum samples to produce
cell pellet at all three screenings. The detailed description of the
biorepository samples has been posted on the ACRIN web site
(available at: http://www.acrin.org/TabID/145/Default.aspx).
All participants from whom samples were collected signed an
informed consent before the prospective collection of samples
using a standardized protocol. All participant information was
entered into a HIPAA-compliant ACRIN central database.
Tissue specimens from those participants who under-
went surgical resection for lung cancer were requested for
future inclusion into a tissue microarray (TMA). These spec-
imens could include tissue from lung tumor, normal lung
tissues, and any tissues from resected metastatic lymph nodes
or other sites. At no time was an invasive or dangerous
procedure performed solely for the purposes of this trial.
SPECIMEN COLLECTION AND PROCESSING
The multiinstitutional design of the NLST ACRIN trial
necessitated the development of a uniform sample procure-
ment protocol. The University of Colorado provided a bio-
specimen and processing kit containing the requisite tubes
and containers. As in any multiinstitutional trial, uniform
collection of patient samples is a daunting task, although we
tried to develop a standardized operating procedure within the
NLST ACRIN study protocol (available at: http://www.acrin.
org/PROTOCOLSUMMARYTABLE/PROTOCOL6654/tabid/
145/Default.aspx). The following samples and processing meth-
ods were used.
1. Blood was drawn from participants into four 8-ml
(yellow top) tubes at their yearly visit. After centrifu-
gation, the plasma and buffy coat were extracted. Buffy
coat was aliquoted into four 2-ml citrate (pink top)
tubes. Plasma was spun to separate cells and debris,
then aliquoted into four 5-ml bar-coded citrate cryovials
(orange top). All blood products were immediately
stored at 80°C.
2. Urine samples were collected and directly placed into
two 5-ml vials for frozen storage.
3. Morning sputum samples were collected by the partic-
ipants into two sputum cups containing Saccamano’s
solution. The participants were instructed to cough on
three successive mornings into each sputum cup. Mail-
ers were provided for direct mailing of sputum samples
to the University of Colorado Specimen Archive. On
receipt, the sputum samples were pelleted by centrifu-
gation and the cell pellets placed directly in a freezer at
80°C.
4. Based on review of surgical pathology reports, paraffin
blocks containing resected tissues (primary lung cancer,
involved lymph nodes and metastases) have been re-
quested retrospectively from the originating pathology
centers by the NLST ACRIN sites. The blocks are
deidentified, assigned a unique label, and forwarded to
the University of California at Los Angeles (UCLA)
Tissue Array Core Facility. At this laboratory, a single
hematoxylin and eosin-stained slide is prepared and
sent to a lung pathologist. The slide is digitized, inter-
preted, and annotated electronically to identify regions
of interest (targets) from which cores for the TMA will
be taken. This image is transferred to film, sized to
match the original paraffin block, and used by the
UCLA TMA laboratory for coring.
STORAGE FACILITY AND CONDITIONS
The NLST ACRIN biorepository is located in dedicated
facilities with state-of-the-art equipment, restricted access,
and excellent security arrangements. All freezers are under
constant monitoring for ventilation and climate control. Qual-
ity assurance mechanisms have been constructed and verified
by site visits.
DATA COLLECTION FORMS
A number of case report forms, including specific ones for
biomarkers, imaging, and follow-up were collected as part of the
screening trial. These forms can be found on the ACRINwebsite
(available at: http://www.acrin.org/Default.aspx?tabid282).
The majority of the forms were completed by the Research
Associates (RAs) electronically or on paper, although some
were completed on paper by the participant. Any questions
not understandable to the participant were explained by the
RA. The RA reviewed all forms at the time of completion for
legibility and completeness, adding any missing data ele-
ments. The completed forms are kept in each participant’s
chart at the site and were entered electronically into the
ACRIN web site.
NLST ACRIN SPECIMEN
BIOREPOSITORY—INTENT
The NLST ACRIN specimen biorepository was devel-
oped as an integral part of the NLST ACRIN screening trial
with the intent to integrate biomarkers into early detection.
Blood, sputum, and urine samples were collected serially as
described earlier in the text, with the primary objective to
validate markers that address diagnostic issues complemen-
tary to or unresolved by conventional screening techniques.
More specifically, three fundamental areas have been the
principal targets of biomarker efforts:
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To Develop Biomarkers Useful in Determining
High-Risk Patients
Current criteria used for most screening trials are age
and smoking history. This approach defines a large number of
individuals at risk for lung cancer, but the overall prevalence
of disease even in the highest risk groups is approximately 1
to 2%.2–4 Nevertheless, individuals in the high-risk popula-
tion often have nonspecific imaging findings that require
further evaluation, and at least 15 to 20% of individuals who
develop lung cancer are not included in this risk-assessment
profile.5 Biomarkers could, in a more efficient manner, help
identify which patients are at highest risk for developing lung
cancer and should, therefore, have an imaging study. Because
the NLST ACRIN biorepository contains longitudinal sam-
ples, prediction models for developing lung cancer can be
tested.
To Validate Biomarkers Useful in Distinguishing
Benign from Malignant Pulmonary Nodules
Detected on Imaging Studies
Participants in CT screening trials often have nonspe-
cific findings, and in some studies, up to 70% will have an
indeterminate nodule.2,4 The majority of individuals require
additional procedures, including CT, positron emission to-
mography, or an invasive procedure. It has been reported that
up to 30% of “highly suspicious” lesions discovered in CT
screening trials proved benign at surgery.2,4,6 If a biomark-
er(s) could immediately determine which patients with an
indeterminate pulmonary nodule had lung cancer or no lung
cancer then further evaluation or treatment could be initiated
without delay.7 There would be no need for a wait and watch
approach with sequential imaging.8 Thus, some patients
would be able to forego follow-up studies or an invasive
procedure, whereas patients with cancer could be treated.
To Validate Biomarker Candidates Predictive
or Prognostic of Tumor Behavior
Once lung cancer is detected, prognosis and therapy are
based on stage at presentation. Nevertheless, lung tumors are
heterogeneous and exhibit a wide spectrum of clinical behav-
ior. This is most notable in patients with early-stage disease,
as almost 40% will develop metastasis.9 Currently, there is no
way to distinguish between individuals who will develop
recurrence and, at the other end of the spectrum, patients with
indolent tumors. Although the concept of a nonaggressive
lung cancer may be difficult to initially understand, the results
of CT screening trials and autopsy series suggest that nonag-
gressive tumors will be detected, and thus, overdiagnosis bias
needs to be considered.2,10–14 That is, tumors that would
never have affected the patient’s natural history are being
detected, diagnosed as lung cancer, and removed despite the
fact that they are not virulent and would never have become
clinically apparent. Although these lesions are radiographi-
cally and histologically indistinguishable from more aggres-
sive tumors, there is currently no way to determine pheno-
type. Biomarkers that could accurately characterize lung
cancer, suggesting the appropriate targeted therapy (predic-
tive markers) and providing outcome information (prognostic
markers), would be invaluable.
ACCESS AND OVERSIGHT OF THE REPOSITORY
The NLST ACRIN biorepository is open to any inves-
tigator interested in validating lung cancer biomarkers. The
application and guidelines are posted on the ACRIN website
(available at: http://www.acrin.org/TabID/145/Default.aspx).
Two largely separate committees were created to oversee
processes and decisions related to the NLST ACRIN biore-
pository. These committees are composed of experts in a
variety of disciplines related to biomarker development, early
lung cancer detection, thoracic imaging, molecular diagnos-
tics, trial design, and statistical analysis. The oversight com-
mittees are as follows.
NLST ACRIN Tissue Bank and Biomarker
Oversight Committee
This group has been responsible for the oversight and
development of policies and procedures that govern the
collection, archiving, quality assurance, and appraisal of the
biorepository. This group assesses the status of the bioreposi-
tory and all quality control efforts.
NLST ACRIN Research Evaluation Panel
Committee
This independent scientific group is composed of in-
vestigators in the biomarker discovery and early detection
communities. They have been charged to:
1. Identify the science that would best be served by use of
the specimens and correlative data.
2. Develop and oversee policies and procedures for the
strategic marketing of this resource to the appropriate
scientists.
3. Develop guidelines and forms for proposals requesting
use of the specimens.
4. Develop guidelines for the peer review of proposals
requesting biospecimens and the terms of fulfillment of
specimens and associated data elements.
PROCESS FOR EVALUATION OF BIOMARKERS
AND DISTRIBUTION OF SAMPLES
An independent peer-review group called the Biospeci-
men Review Committee has been established by the NLST
ACRIN Research Evaluation Panel to review all proposals
requesting the use of NLST ACRIN biospecimens. The
review will include members of ACRIN, NLST ACRIN
investigators, and ad hoc members of the lung cancer scien-
tific community who have expertise in biomolecular technol-
ogies and the evaluations under consideration.
REVIEW CRITERIA FOR APPLICATIONS TO USE
NLST ACRIN BIOSPECIMENS
Review criteria are based on scientific merit and com-
patibility with NLST ACRIN objectives. All NIH review
criteria will be applicable, although the following objectives
will be strongly considered:
Patz Jr. et al. Journal of Thoracic Oncology • Volume 5, Number 10, October 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer1504
1. Scientific merit.
2. Technical parameters: reproducibility, sensitivity, spec-
ificity, throughput, and automation.
3. Clinical or scientific impact.
4. Practicality and feasibility; e.g., cost, required sample
size, and amount of biospecimen required.
5. Collaborative strength, including contribution of re-
sources and technology.
APPLICATION AND REVIEW PROCESS
The NLST ACRIN biospecimen application is a two-
part process administrered directly by ACRIN. The ad hoc
committees review all proposals for access to the biore-
pository specimens. The complete submission and review
process are detailed on the ACRIN website (available at:
http://www.acrin.org/TabID/145/Default.aspx). The NIH/
NCI does not receive or review applications.
1. The application and review processes are two-tiered. A
Pre-Application Form limited to three pages must be
submitted to ACRIN Headquarters 10 weeks before the
full application deadlines. The pre-application includes
investigator information, project title, project hypothe-
sis, experimental approach and a detailed description of
biospecimen types, quantities, and specific characteris-
tics. Applicants are strongly encouraged to collaborate
with ACRIN investigators and the ACRIN Statistical
Center on the project.
2. Investigators with Pre-Applications approved by the
ACRIN Biospecimen Review Committees are invited to
submit a full proposal. The full proposal should not
exceed five pages. A detailed background and rationale
are not necessary, but presentation of preliminary data
documenting the performance of the proposed marker is
mandatory.
3. Copies of the Full Application received by the desig-
nated receipt date undergo scientific review by the
Biospecimen Review Committee and logistical review
by the ACRIN Data Access Committee. Disparities
between the two reviews are reconciled by joint com-
mittee input. Review of full applications is completed
within 6 weeks.
4. The results of review are forwarded by ACRIN Head-
quarters to the ACRIN NLST Executive Committee and
the independent NLST Data and Safety Monitoring
Board, both of which can respond to the approval
recommendations.
The Cancer Imaging Program, NCI, which funds the
NLST ACRIN, is advised of final decisions.
5. ACRIN Headquarters communicates review decisions
and forwards evaluations to the principal investigators.
STRUCTURE AND FORMAT OF VALIDATION
STUDY PROPOSALS
The following items will be requested for the proposal:
Y Clinical relationship to early detection or diagnosis.
Y Background and significance.
Y Preliminary data and methods.
Y Data analysis plan.
Y Collaborations.
Y Future plans.
DATA ANALYSIS, DATA SHARING,
CHRONOLOGY OF REPORTING, AND
INTELLECTUAL PROPERTY MANAGEMENT
All analyses of the performance characteristics of bi-
omarker assays will be centralized at the ACRIN Biostatistics
Center located at Brown University. The clinical data asso-
ciated with specimens will not be released with the biospeci-
mens until 1 year after publication of the NLST primary end
point. After this time, analyses may be collaborative between
the investigators and ACRIN Biostatistics Center. This ap-
proach ensures the integrity of the trial end points and could
facilitate the integration of multiple platforms applied on
same samples. It is hoped that the complementary nature of
different biomarkers will improve diagnostic accuracies and
prediction rates.
Institutions involved in NLST ACRIN biomarker vali-
dation studies must meet the NIH policies for sharing of data.
The NLST ACRIN biomarker initiative is premised on the
belief that an established, integrated and multidisciplinary
environment will expedite clinical applications of biomarker
validation.
Data sharing of raw and processed data will be agreed
upon at the time of submission of the Full Application and in
accordance with the NIH Grants Policy Statement (available
at: http://grants.nih.gov/grants/policy/nihgps/) and the Princi-
ples and Guidelines for Recipients of NIH Research Grants
and Contracts on Obtaining and Disseminating Biomedical
Research.
Investigators from the community and ACRIN will
exercise intellectual property rights, should any be generated
through this proposal, while making such research resources
available to the broader scientific community one year after
samples are distributed, consistent with achieving the goals of
the program. Collaborations may occur with industry, but the
raw data generated on NLST-ACRIN samples should remain
available to the larger community in a reasonable time frame.
SUMMARY
Well annotated longitudinal samples were uniformly
collected and stored in a central biorepository in the context
of a screening trial, with a primary end point to determine
whether screening for lung cancer with low-dose helical CT
reduces mortality. The NLST ACRIN specimen bank repre-
sents a unique opportunity to complement imaging and
validate early detection biomarkers for lung cancer. Bi-
omarkers have the potential to improve diagnostic effi-
ciency, reduce cost, and affect the evaluation and manage-
ment of these patients. Although imaging has played an
important role in diagnosing, staging, and following pa-
tients with lung cancer, new strategies using biomarkers
offer alternative opportunities to address unresolved diag-
nostic issues in oncology.
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